Abstract
With the advent of DNA microarray analysis, it is now possible to examine the response of virtually the entire human genome to cellular drug exposure and to uncover a wide variety of genes correlating with the establishment of drug resistance. This relatively new field of “pharmacogenomics” is likely to vastly increase our understanding of the mechanisms of drug action and how cells respond and adapt to drug exposure. However, DNA microarray studies typically result in the identification of hundreds of genes that may or may not be of relevance in vivo --- particularly when large, genetically diverse study populations are used. The challenge to the researcher is to design experimental systems and approaches which minimize variability in the data, increase the reproducibility amongst experiments, allow array data from multiple experiments to be assessed by a variety of statistical, supervised learning, and data clustering approaches, and provide a clear link between drug response and the expression of specific genes. This review provides a description and critical analysis of recent studies on the pharmacogenomics of drug response and discusses current guidelines and approaches for the performance and analysis of DNA microarray experiments in this area.
Keywords: pharmacogenomics, dna microarray, chemotherapy, drug response, drug resistance, miame standards, review
Current Topics in Medicinal Chemistry
Title: The Use of DNA Microarrays to Investigate the Pharmacogenomics of Drug Response in Living Systems
Volume: 4 Issue: 13
Author(s): David J. Villeneuve and Amadeo M. Parissenti
Affiliation:
Keywords: pharmacogenomics, dna microarray, chemotherapy, drug response, drug resistance, miame standards, review
Abstract: With the advent of DNA microarray analysis, it is now possible to examine the response of virtually the entire human genome to cellular drug exposure and to uncover a wide variety of genes correlating with the establishment of drug resistance. This relatively new field of “pharmacogenomics” is likely to vastly increase our understanding of the mechanisms of drug action and how cells respond and adapt to drug exposure. However, DNA microarray studies typically result in the identification of hundreds of genes that may or may not be of relevance in vivo --- particularly when large, genetically diverse study populations are used. The challenge to the researcher is to design experimental systems and approaches which minimize variability in the data, increase the reproducibility amongst experiments, allow array data from multiple experiments to be assessed by a variety of statistical, supervised learning, and data clustering approaches, and provide a clear link between drug response and the expression of specific genes. This review provides a description and critical analysis of recent studies on the pharmacogenomics of drug response and discusses current guidelines and approaches for the performance and analysis of DNA microarray experiments in this area.
Export Options
About this article
Cite this article as:
Villeneuve J. David and Parissenti M. Amadeo, The Use of DNA Microarrays to Investigate the Pharmacogenomics of Drug Response in Living Systems, Current Topics in Medicinal Chemistry 2004; 4 (13) . https://dx.doi.org/10.2174/1568026043387610
DOI https://dx.doi.org/10.2174/1568026043387610 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Astatine-211: Production and Availability
Current Radiopharmaceuticals Proteases as Anti-Cancer Targets - Molecular and Biological Basis for Development of Inhibitor-Like Drugs Against Cancer
Anti-Cancer Agents in Medicinal Chemistry PSEN1 Promoter Demethylation in Hyperhomocysteinemic TgCRND8 Mice is the Culprit, not the Consequence
Current Alzheimer Research Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design Advances in Methods for Therapeutic Peptide Discovery, Design and Development
Current Pharmaceutical Biotechnology Immune Response to Herpes Simplex Virus and γ134.5 Deleted HSV Vectors
Current Gene Therapy Down with the Erythropoietin. Long Live the Erythropoietin !
Current Drug Targets The Role of the Anti-Amyloidogenic Secretase ADAM10 in Shedding the APP-like Proteins
Current Alzheimer Research The HOX Genes Network in Uro-Genital Cancers: Mechanisms and Potential Therapeutic Implications
Current Medicinal Chemistry Bioinformatic Application in Proteomic Research on Biomarker Discovery and Drug Target Validation
Current Bioinformatics Experimental Approaches to Tse Prevention Via Inhibition of Prion Formation
Protein & Peptide Letters Theories and Treatment of Drug Dependency: A Neurochemical Perspective
Current Molecular Pharmacology Central Serotonin2C Receptor: From Physiology to Pathology
Current Topics in Medicinal Chemistry The Long Non-Coding RNAs in Neurodegenerative Diseases: Novel Mechanisms of Pathogenesis
Current Alzheimer Research Neuroimmune Aspects of Sjogren`s Syndrome: Role of VIP/VPAC System in Immune and Salivary Gland Epithelial Cell Function
Current Pharmaceutical Design Relationships Between Mitochondria and Neuroinflammation: Implications for Alzheimer’s Disease
Current Topics in Medicinal Chemistry Patenting Penicillium Strains
Recent Patents on Biotechnology Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Neuroinflammation: A Therapeutic Target of Cotinine for the Treatment of Psychiatric Disorders?
Current Pharmaceutical Design Oxidative stress and Parkinson’s disease: New hopes in treatment with herbal antioxidants
Current Pharmaceutical Design